Arthritis - Pipeline Review, H2 2014

Arthritis - Pipeline Review, H2 2014 is a new market research publication announced by Reportstack. 

The report provides an overview of the Arthritis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides a snapshot of the global therapeutic landscape of Arthritis

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 

- The report reviews key players involved in the therapeutics development for Arthritis and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects 

- A review of the Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Arthritis pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Arthritis

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Eli Lilly and Company GlaxoSmithKline plc Nemucore Medical Innovations, Inc. Taisho Pharmaceutical Co., Ltd. Sylentis S.A. Astellas Pharma Inc. Eisai Co., Ltd. Bone Medical Limited Momenta Pharmaceuticals, Inc. Can-Fite BioPharma Ltd. Lexicon Pharmaceuticals, Inc. CSL Limited WhanIn Pharmaceutical Co., Ltd. Oscotec Inc. Viron Therapeutics, Inc. PLx Pharma Inc. Endocyte, Inc. Cardax Pharmaceuticals, Inc. Taiwan Liposome Company, Ltd. NasVax Ltd. CalciMedica, Inc. Zyngenia, Inc. SelectX Pharmaceuticals, Inc. DoNatur GmbH CellAct Pharma GmbH Arcarios BV Inbiopro Solutions Pvt. Ltd. Sagene Pharmaceuticals, Inc. vida therapeutics inc. Dong-A Socio Group

To view the table of contents and know more details please visit Arthritis - Pipeline Review, H2 2014

Dyslipidemia - Pipeline Review, H2 2014

Dyslipidemia - Pipeline Review, H2 2014 is a new market research publication announced by Reportstack. 

The report provides an overview of the Dyslipidemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dyslipidemia

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 

- The report reviews key players involved in the therapeutics development for Dyslipidemia and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects 

- A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Dyslipidemia pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Dyslipidemia

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Amgen Inc. AstraZeneca PLC GlaxoSmithKline plc Daiichi Sankyo Company, Limited Merck & Co., Inc. Takeda Pharmaceutical Company Limited Teijin Pharma Limited Novartis AG Biocon Limited Chong Kun Dang Pharmaceutical Corp. Dr. Reddy's Laboratories Limited Kissei Pharmaceutical Co., Ltd. Kowa Company, Ltd. Zydus Cadila Healthcare Limited Genfit SA Nippon Chemiphar Co., Ltd. Torrent Pharmaceuticals Limited Debiopharm International S.A. Jenrin Discovery, Inc. Lipicard Technologies Limited Cadila Pharmaceuticals Ltd. Spherix Incorporated Arisaph Pharmaceuticals, Inc. Alder Biopharmaceuticals Inc. Catabasis Pharmaceuticals, Inc. Cerenis Therapeutics SA Pharmena SA Reviva Pharmaceuticals Inc. Kotobuki Pharmaceutical Co., Ltd. High Point Pharmaceuticals, LLC Kadmon Corporation, LLC Dezima Pharma B.V.

To view the table of contents and know more details please visit Dyslipidemia - Pipeline Review, H2 2014

Inflammatory Pain - Pipeline Review, H2 2014

Inflammatory Pain - Pipeline Review, H2 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Inflammatory Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides a snapshot of the global therapeutic landscape of Inflammatory Pain

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 

- The report reviews key players involved in the therapeutics development for Inflammatory Pain and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects 

- A review of the Inflammatory Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Inflammatory Pain pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Inflammatory Pain

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Inflammatory Pain pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Boehringer Ingelheim GmbH Kyowa Hakko Kirin Co., Ltd. Shionogi & Co., Ltd. AstraZeneca PLC MedImmune, LLC Merck & Co., Inc. Takeda Pharmaceutical Company Limited Glenmark Pharmaceuticals Ltd. Pfizer Inc. Evotec AG Anavex Life Sciences Corp. Array BioPharma Inc. Pluristem Therapeutics Inc. BCN Peptides, S.A. Upsher-Smith Laboratories, Inc. Grunenthal GmbH Integral Molecular, Inc. AngioChem Inc. Asahi Kasei Pharma Corp. Hydra Biosciences, Inc. NeurAxon, Inc. Cara Therapeutics, Inc. CLL Pharma Dompe Farmaceutici S.p.A. Lohocla Research Corporation MAKScientific, LLC RaQualia Pharma Inc. Sunovion Pharmaceuticals Inc. Adynxx, Inc. Kareus Therapeutics, SA AnaBios Corporation Creabilis SA Istituto Italiano di Tecnologia Infirst Healthcare Limited AbbVie Inc. Epirus Biopharmaceuticals, Inc.

To view the table of contents and know more details please visit Inflammatory Pain - Pipeline Review, H2 2014

Spinal Cord Injury - Pipeline Review, H2 2014

Spinal Cord Injury - Pipeline Review, H2 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Spinal Cord Injury’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Spinal Cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Cord Injury and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides a snapshot of the global therapeutic landscape of Spinal Cord Injury

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 

- The report reviews key players involved in the therapeutics development for Spinal Cord Injury and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects 

- A review of the Spinal Cord Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Spinal Cord Injury pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Spinal Cord Injury

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Spinal Cord Injury pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Athersys, Inc. Quark Pharmaceuticals, Inc. Acorda Therapeutics, Inc. BioMarin Pharmaceutical Inc. Lpath, Inc. Remedy Pharmaceuticals, Inc. TissueGene, Inc. BioArctic Neuroscience AB Grupo Ferrer Internacional, S.A. AIM Therapeutics Inc. Omeros Corporation FirstString Research, Inc. Stemedica Cell Technologies, Inc. SanBio, Inc. Sirnaomics, Inc. Lipopharma Therapeutics SL Mapreg S.A.S. Asubio Pharma Co., Ltd. PharmatrophiX, Inc. RhinoCyte, Inc. MandalMed, Inc. Faron Pharmaceuticals Oy K-Stemcell Co., Ltd. Vicore Pharma AB Axerion Therapeutics, Inc. Genervon Biopharmaceuticals, LLC Hemostemix Ltd

To view the table of contents and know more details please visit Spinal Cord Injury - Pipeline Review, H2 2014

Duchenne Muscular Dystrophy - Pipeline Review, H2 2014

Duchenne Muscular Dystrophy - Pipeline Review, H2 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Duchenne Muscular Dystrophy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by A team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 

- The report reviews key players involved in the therapeutics development for Duchenne Muscular Dystrophy and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects 

- A review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Sanofi Eli Lilly and Company Daiichi Sankyo Company, Limited Nippon Shinyaku Co., Ltd. Zambon Company S.p.A. Sarepta Therapeutics, Inc. NicOx S.A. Lexicon Pharmaceuticals, Inc. Galapagos NV Summit Corporation plc Santhera Pharmaceuticals Holding AG Shenzhen Beike Biotechnology Co., Ltd. Italfarmaco S.p.A. Acceleron Pharma, Inc. Prosensa Holding B.V. Catabasis Pharmaceuticals, Inc. Nobelpharma Co., Ltd. PTC Therapeutics, Inc. Reata Pharmaceuticals, Inc. Fate Therapeutics, Inc. N-Gene Research Laboratories, Inc. Asklepios BioPharmaceutical, Inc. Genethon miRagen Therapeutics, Inc. Prosensa Therapeutics B.V. Tarix Pharmaceuticals LTD. EryDel SPA Myomics, Inc. Prothelia, Inc. ReveraGen BioPharma, Inc. Retrophin, LLC

To view the table of contents and know more details please visit Duchenne Muscular Dystrophy - Pipeline Review, H2 2014

Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2014

Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Diffuse Large B-Cell Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by A team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 

- The report reviews key players involved in the therapeutics development for Diffuse Large B-Cell Lymphoma and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects 

- A review of the Diffuse Large B-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Diffuse Large B-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Bristol-Myers Squibb Company Boehringer Ingelheim GmbH F. Hoffmann-La Roche Ltd. Amgen Inc. Sanofi AstraZeneca PLC GlaxoSmithKline plc Seattle Genetics, Inc. Genentech, Inc. MedImmune, LLC Gilead Sciences, Inc. Merck & Co., Inc. Infinity Pharmaceuticals, Inc. Celltrion, Inc. Millennium Pharmaceuticals, Inc. Novartis AG Astellas Pharma Inc. ImmunoGen, Inc. Ono Pharmaceutical Co., Ltd. Taiho Pharmaceutical Co., Ltd. Sandoz Inc. Celgene Corporation Onyx Pharmaceuticals, Inc. Bayer AG Incyte Corporation Immunomedics, Inc. Idera Pharmaceuticals, Inc. Curis, Inc. Portola Pharmaceuticals, Inc. Pharmacyclics, Inc. Senesco Technologies, Inc. Spectrum Pharmaceuticals, Inc. Affimed Therapeutics AG Memgen, LLC. Priaxon AG Respiratorius AB Constellation Pharmaceuticals, Inc. ProNAi Therapeutics, Inc. Cell>Point Aprogen, Inc. Selvita S.A Karyopharm Therapeutics, Inc. Kite Pharma, Inc. Arrien Pharmaceuticals, LLC AbbVie Inc. Mirati Therapeutics Inc.

To view the table of contents and know more details please visit Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2014

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2014

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by A team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris)

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 

- The report reviews key players involved in the therapeutics development for Plaque Psoriasis (Psoriasis Vulgaris) and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects 

- A review of the Plaque Psoriasis (Psoriasis Vulgaris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris)

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Johnson & Johnson Kyowa Hakko Kirin Co., Ltd. Valeant Pharmaceuticals International, Inc. Amgen Inc. Celltrion, Inc. Novartis AG Biocon Limited LEO Pharma A/S Pfizer Inc. UCB S.A. Celgene Corporation Idera Pharmaceuticals, Inc. Almirall, S.A. Protalix BioTherapeutics, Inc. Biotie Therapies Corp. R-Tech Ueno, Ltd. Anacor Pharmaceuticals, Inc. Circassia Holdings Ltd. Coronado Biosciences, Inc. TetraLogic Pharmaceuticals Vascular Biogenics Ltd. Invion Limited ISDIN Promius Pharma, LLC Avesthagen Limited Maruho Co., Ltd. CalciMedica, Inc. Biosidus S.A. XBiotech USA, Inc. Forward Pharma A/S Delenex Therapeutics AG Creabilis SA Dermira Inc. Kadmon Corporation, LLC Cormorant Pharmaceuticals AB Epirus Biopharmaceuticals, Inc. AlphaMab Co., Ltd

To view the table of contents and know more details please visit Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2014

Migraine - Pipeline Review, H2 2014

Migraine - Pipeline Review, H2 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Migraine’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by A team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides a snapshot of the global therapeutic landscape of Migraine

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 

- The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects 

- A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Migraine pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Migraine

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Bristol-Myers Squibb Company Allergan, Inc. Amgen Inc. Eli Lilly and Company Questcor Pharmaceuticals, Inc. BioDelivery Sciences International, Inc. Nektar Therapeutics Merck & Co., Inc. TheraJect, Inc. Biofrontera AG Astellas Pharma Inc. Pfizer Inc. Vertex Pharmaceuticals Incorporated Impax Laboratories, Inc. Revance Therapeutics, Inc. IntelGenx Corp. Avanir Pharmaceuticals, Inc. Paladin Labs Inc. Transcept Pharmaceuticals, Inc. Pozen, Inc. D-Pharm Ltd. Ache Laboratorios Farmaceuticos S/A Alder Biopharmaceuticals Inc. CoLucid Pharmaceuticals, Inc. Charleston Laboratories, Inc. Pantarhei Bioscience BV NeurAxon, Inc. Noxxon Pharma AG Monosol Rx, LLC Shin Nippon Biomedical Laboratories, Ltd. Medestea Research & Production S.p.A. Proreo Pharma AG Heptares Therapeutics Ltd. iCeutica, Inc. Trigemina, Inc. Istituto Italiano di Tecnologia Northern Light Pharmaceuticals AB

To view the table of contents and know more details please visit Migraine - Pipeline Review, H2 2014

Bladder Cancer - Pipeline Review, H2 2014

Bladder Cancer - Pipeline Review, H2 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Bladder Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by A team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bladder Cancer

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 

- The report reviews key players involved in the therapeutics development for Bladder Cancer and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects 

- A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Bladder Cancer pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Bladder Cancer

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Shionogi & Co., Ltd. AstraZeneca PLC Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Bioniche Life Sciences, Inc. Bavarian Nordic A/S Biotest AG Daiichi Sankyo Company, Limited Merck & Co., Inc. Samyang Holdings Corporation Astellas Pharma Inc. Eisai Co., Ltd. Marina Biotech, Inc. Genmab A/S Celgene Corporation Bayer AG Advaxis, Inc. Evotec AG Immunomedics, Inc. Alnylam Pharmaceuticals, Inc. Oncogenex Pharmaceuticals, Inc. Dendreon Corporation Sanochemia Pharmazeutika AG OncoTherapy Science, Inc. Quest PharmaTech Inc. Synta Pharmaceuticals Corp. Med Discovery SA Hutchison MediPharma Limited Altor BioScience Corporation Telormedix SA Gene Signal International SA Merrimack Pharmaceuticals, Inc. Innate Therapeutics Limited Stemline Therapeutics, Inc. BioCancell Therapeutics, Inc. AndroScience Corporation Serum Institute of India Limited Dompe Farmaceutici S.p.A. NuCana BioMed Limited Polaris Group Serometrix, LLC Regulon Inc. SentoClone International AB Optimum Therapeutics, LLC Lipella Pharmaceuticals, Inc. APIM Therapeutics AS EntreChem, S.L. Immunservice GmbH Qu Biologics Inc. Panacela Labs, Inc. Tolero Pharmaceuticals, Inc. Oncopeptides AB DormaTarg, Inc. AlphaMab Co., Ltd Mirati Therapeutics Inc.

To view the table of contents and know more details please visit Bladder Cancer - Pipeline Review, H2 2014

Osteoarthritis Pain - Pipeline Review, H2 2014

Osteoarthritis Pain - Pipeline Review, H2 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Osteoarthritis Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 

- The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects 

- A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Osteoarthritis Pain pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Boehringer Ingelheim GmbH Allergan, Inc. Eli Lilly and Company Pfizer Inc. Purdue Pharma L.P. Teva Pharmaceutical Industries Limited BioChemics, Inc. Addex Therapeutics Ltd Nuvo Research Inc. Pozen, Inc. Futura Medical plc AcurePharma AB Rottapharm SpA QRxPharma Limited Iroko Pharmaceuticals, LLC Antibe Therapeutics, Inc. Flexion Therapeutics, Inc. Afferent Pharmaceuticals, Inc. iCeutica, Inc. Ampio Pharmaceuticals, Inc. AbbVie Inc. Akron Molecules AG

To view the table of contents and know more details please visit Osteoarthritis Pain - Pipeline Review, H2 2014